Bakterielle Fehlbesiedlung des Dünndarms (SIBO) – Therapie, Ernährung, Mikrobiom

SIBO (small intestinal bacterial overgrowth) ist durch eine bakterielle Überwucherung oder Fehlbesiedlung des Dünndarms in Kombination mit gastrointestinalen Symptomen definiert. Intestinale Stase, Hypochlorhydrie, Immundefizienz, Alter u.a. sind auslösende Faktoren. Der Einfluss der Ernährung auf die Entwicklung einer SIBO ist zwar naheliegend – bisher aber unzureichend untersucht.

Abstract

SIBO (small intestinal bacterial overgrowth) is defined by bacterial overgrowth or colonization of the small intestine in combination with gastrointestinal symptoms such as bloating, nausea, pain, diarrhoea, malabsorption and food intolerance. SIBO can be caused by various mechanisms such as reduced intestinal motility, altered gastrointestinal anatomy, reduced gastric acid or pancreatic enzyme production, altered bile acid metabolism, or immune defects. Accordingly, SIBO often develops secondary to different underlying diseases.

Diet has a fundamental influence on the composition of the intestinal microbiome and is therefore also a potential pathomechanism in SIBO. Furthermore, food intolerances are common in SIBO patients. However, both aspects have so far been insufficiently investigated. Nevertheless, elemental diets, carbohydrate-reduced diets, as well as pre- and probiotics are potential therapy options.

This article provides a summary of current knowledge on the pathophysiology, diagnosis and treatment of SIBO, with particular emphasis on the role of nutrition and the microbiome.

Schlüsselwörter

SIBO - Reizdarmsyndrom - Mikrobiom - Nahrungsmittelunverträglichkeit - Low-FODMAP-Diät

Keywords

SIBO - irritable bowel syndrome - microbiome - food intolerance - low-FODMAP diet

• Literatur

• 1 Shalon D, Culver RN, Grembi JA. et al. Profiling the human intestinal environment under physiological conditions. Nature 2023; 617: 581-591
• 2 Pimentel M, Saad RJ, Long MD. et al. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol 2020; 115: 165-178
• 3 Hammer HF, Fox MR, Keller J. et al. European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus. United Eur Gastroenterol J 2022; 10: 15-40
• 4 Ghoshal UC, Sachdeva S, Ghoshal U. et al. Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association. Indian J Gastroenterol 2022; 41: 483-507
• 5 Bushyhead D, Quigley EMM. Small intestinal bacterial overgrowth – pathophysiology and its implications for definition and management. Gastroenterology 2022; 163: 593-607
• 6 Sellge G. Ernährung bei bakterieller Fehlbesiedlung des Dünndarms. Gastroenterologie 2024; 19: 22-29
• 7 Sellge G. Bakterielle Fehlbesiedlung des Dünndarms. Aktuel Ernahrungsmed 2024; 49: 156-172
• 8 Barlow JT, Leite G, Romano AE. et al. Quantitative sequencing clarifies the role of disruptor taxa, oral microbiota, and strict anaerobes in the human small-intestine microbiome. Microbiome 2021; 9: 1-17
• 9 Shah A, Talley NJ, Jones M. et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol 2020; 115: 190-201
• 10 Leite G, Morales W, Weitsman S. et al. The duodenal microbiome is altered in small intestinal bacterial overgrowth. PLoS One 2020; 15: 1-17
• 11 Böhn L, Störsrud S, Törnblom H. et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013; 108: 634-641
• 12 Kolodziejczyk AA, Zheng D, Elinav E. Diet–microbiota interactions and personalized nutrition. Nat Rev Microbiol 2019; 17: 742-753
• 13 Wielgosz-Grochowska JP, Domanski N, Drywień ME. Efficacy of an irritable bowel syndrome diet in the treatment of small intestinal bacterial overgrowth: a narrative review. Nutrients 2022; 14: 3382
• 14 Tuganbaev T, Mor U, Bashiardes S. et al. Diet diurnally regulates small intestinal microbiome-epithelial-immune homeostasis and enteritis. Cell 2020; 182: 1441-1459.e21
• 15 Singh R, Zogg H, Wei L. et al. Gut microbial dysbiosis in the pathogenesis of gastrointestinal dysmotility and metabolic disorders. J Neurogastroenterol Motil 2021; 27: 19-34
• 16 Gatta L, Scarpignato C, McCallum RW. et al. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017; 45: 604-616
• 17 Lauritano EC, Gabrielli M, Scarpellini E. et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008; 103: 2031-2035
• 18 Pimentel M, Cash BD, Lembo A. et al. Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity. Dig Dis Sci 2017; 62: 2455-2463
• 19 Takakura W, Rezaie A, Chey WD. et al. Symptomatic response to antibiotics in patients with small intestinal bacterial overgrowth: a systematic review and meta-analysis. J Neurogastroenterol Motil 2024; 30: 7-16
• 20 Pimentel M, Constantino T, Kong Y. et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci 2004; 49: 73-77
• 21 Zhong C, Qu C, Wang B. et al. Probiotics for preventing and treating small intestinal bacterial overgrowth. J Clin Gastroenterol 2017; 51: 300-311
• 22 Furnari M, Parodi A, Gemignani L. et al. Clinical trial: The combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2010; 32: 1000-1006
• 23 Ong DK, Mitchell SB, Barrett JS. et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25: 1366-1373
• 24 Staudacher HM, Rossi M, Kaminski T. et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. Neurogastroenterol Motil 2022; 34: e14241
• 25 Xu F, Li N, Wang C. et al. Clinical efficacy of fecal microbiota transplantation for patients with small intestinal bacterial overgrowth: a randomized, placebo-controlled clinic study. BMC Gastroenterol 2021; 21: 1-10